Nocturia, nocturnal incontinence prevalence, and response to anticholinergic and behavioral therapy

M. P. FitzGerald, G. Lemack, T. Wheeler, H. J. Litman

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

To determine whether participants in the behavior enhances drug reduction of incontinence (BE-DRI) trial experienced reduction in the frequency of nocturia and/or nocturnal leakage during treatment with antimuscarinic phamacotherapy with or without additional behavioral therapy. We analyzed urinary diary data relating to nocturia and nocturnal incontinence before and after 8 weeks of study treatment in the BE-DRI trial, in which patients were randomly assigned to receive drug therapy with tolterodine tartrate extended-release capsules 4 mg alone or in combination with behavioral training. Chi-square tests assessed whether nocturia and nocturnal incontinence prevalence varied by treatment arm and paired t tests assessed the change in mean frequency of nocturia and nocturnal leakage. Among 305 women, 210 (69%) had an average of at least one nocturia episode at baseline. There were small but statistically significant differences (p < 0.001) in mean nocturia frequency and nocturnal incontinence frequency with both treatments after 8 weeks, but no significant difference between study treatment groups. Among these urge incontinent women, tolterodine with or without supervised behavioral therapy had little impact on either nocturic frequency or nocturnal incontinence.

Original languageEnglish (US)
Pages (from-to)1545-1550
Number of pages6
JournalInternational Urogynecology Journal and Pelvic Floor Dysfunction
Volume19
Issue number11
DOIs
StatePublished - 2008

Fingerprint

Nocturia
Cholinergic Antagonists
Therapeutics
Muscarinic Antagonists
Chi-Square Distribution
Pharmaceutical Preparations
Capsules
Drug Therapy

Keywords

  • Antimuscarinic therapy
  • Behavioral therapy
  • Lower urinary tract
  • Nocturia
  • Urge incontinence

ASJC Scopus subject areas

  • Urology
  • Obstetrics and Gynecology

Cite this

Nocturia, nocturnal incontinence prevalence, and response to anticholinergic and behavioral therapy. / FitzGerald, M. P.; Lemack, G.; Wheeler, T.; Litman, H. J.

In: International Urogynecology Journal and Pelvic Floor Dysfunction, Vol. 19, No. 11, 2008, p. 1545-1550.

Research output: Contribution to journalArticle

@article{9316aab1185d42dbb998dfe5e48f67a2,
title = "Nocturia, nocturnal incontinence prevalence, and response to anticholinergic and behavioral therapy",
abstract = "To determine whether participants in the behavior enhances drug reduction of incontinence (BE-DRI) trial experienced reduction in the frequency of nocturia and/or nocturnal leakage during treatment with antimuscarinic phamacotherapy with or without additional behavioral therapy. We analyzed urinary diary data relating to nocturia and nocturnal incontinence before and after 8 weeks of study treatment in the BE-DRI trial, in which patients were randomly assigned to receive drug therapy with tolterodine tartrate extended-release capsules 4 mg alone or in combination with behavioral training. Chi-square tests assessed whether nocturia and nocturnal incontinence prevalence varied by treatment arm and paired t tests assessed the change in mean frequency of nocturia and nocturnal leakage. Among 305 women, 210 (69{\%}) had an average of at least one nocturia episode at baseline. There were small but statistically significant differences (p < 0.001) in mean nocturia frequency and nocturnal incontinence frequency with both treatments after 8 weeks, but no significant difference between study treatment groups. Among these urge incontinent women, tolterodine with or without supervised behavioral therapy had little impact on either nocturic frequency or nocturnal incontinence.",
keywords = "Antimuscarinic therapy, Behavioral therapy, Lower urinary tract, Nocturia, Urge incontinence",
author = "FitzGerald, {M. P.} and G. Lemack and T. Wheeler and Litman, {H. J.}",
year = "2008",
doi = "10.1007/s00192-008-0687-7",
language = "English (US)",
volume = "19",
pages = "1545--1550",
journal = "International Urogynecology Journal and Pelvic Floor Dysfunction",
issn = "0937-3462",
publisher = "Springer London",
number = "11",

}

TY - JOUR

T1 - Nocturia, nocturnal incontinence prevalence, and response to anticholinergic and behavioral therapy

AU - FitzGerald, M. P.

AU - Lemack, G.

AU - Wheeler, T.

AU - Litman, H. J.

PY - 2008

Y1 - 2008

N2 - To determine whether participants in the behavior enhances drug reduction of incontinence (BE-DRI) trial experienced reduction in the frequency of nocturia and/or nocturnal leakage during treatment with antimuscarinic phamacotherapy with or without additional behavioral therapy. We analyzed urinary diary data relating to nocturia and nocturnal incontinence before and after 8 weeks of study treatment in the BE-DRI trial, in which patients were randomly assigned to receive drug therapy with tolterodine tartrate extended-release capsules 4 mg alone or in combination with behavioral training. Chi-square tests assessed whether nocturia and nocturnal incontinence prevalence varied by treatment arm and paired t tests assessed the change in mean frequency of nocturia and nocturnal leakage. Among 305 women, 210 (69%) had an average of at least one nocturia episode at baseline. There were small but statistically significant differences (p < 0.001) in mean nocturia frequency and nocturnal incontinence frequency with both treatments after 8 weeks, but no significant difference between study treatment groups. Among these urge incontinent women, tolterodine with or without supervised behavioral therapy had little impact on either nocturic frequency or nocturnal incontinence.

AB - To determine whether participants in the behavior enhances drug reduction of incontinence (BE-DRI) trial experienced reduction in the frequency of nocturia and/or nocturnal leakage during treatment with antimuscarinic phamacotherapy with or without additional behavioral therapy. We analyzed urinary diary data relating to nocturia and nocturnal incontinence before and after 8 weeks of study treatment in the BE-DRI trial, in which patients were randomly assigned to receive drug therapy with tolterodine tartrate extended-release capsules 4 mg alone or in combination with behavioral training. Chi-square tests assessed whether nocturia and nocturnal incontinence prevalence varied by treatment arm and paired t tests assessed the change in mean frequency of nocturia and nocturnal leakage. Among 305 women, 210 (69%) had an average of at least one nocturia episode at baseline. There were small but statistically significant differences (p < 0.001) in mean nocturia frequency and nocturnal incontinence frequency with both treatments after 8 weeks, but no significant difference between study treatment groups. Among these urge incontinent women, tolterodine with or without supervised behavioral therapy had little impact on either nocturic frequency or nocturnal incontinence.

KW - Antimuscarinic therapy

KW - Behavioral therapy

KW - Lower urinary tract

KW - Nocturia

KW - Urge incontinence

UR - http://www.scopus.com/inward/record.url?scp=53249100395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53249100395&partnerID=8YFLogxK

U2 - 10.1007/s00192-008-0687-7

DO - 10.1007/s00192-008-0687-7

M3 - Article

C2 - 18704249

AN - SCOPUS:53249100395

VL - 19

SP - 1545

EP - 1550

JO - International Urogynecology Journal and Pelvic Floor Dysfunction

JF - International Urogynecology Journal and Pelvic Floor Dysfunction

SN - 0937-3462

IS - 11

ER -